title: [Modern treatment in acute coronary syndrome].
abstract: The "acute coronary syndrome" (ACS) is a life threatening condition. In patients                     with ST-segment elevation myocardial infarction (STEMI) an immediate reperfusion                     therapy is indicated. Primary percutaneous coronary intervention (PCI) is the                     gold standard. In ACS without ST-segment elevation (NSTE-ACS) coronary                     angiography should be performed within 72 hours in patients with risk factors.                     Depending on the coronary anatomy treatment options are PCI, aorto-coronary                     bypass surgery or sole medical therapy. The antiplatelet therapy has a key role                     in ACS. In addition to acetylsalicylic acid (ASA) another platelet aggregation                     inhibitor should be given for 12 months. For the majority of patients ticagrelor                     and prasugrel are the agents of first choice, because both act faster and                     stronger than clopidogrel. In patients at high risk of bleeding clopidogrel                     remains the preferable antiplatelet agent. In addition to antiplatelet treatment                     anticoagulant therapy is necessary in ACS-patients.
authors.affiliation: Medizinische Klinik B, Herzzentrum Ludwigshafen. bauer-timm@gmx.de
authors.forename: T
authors.initials: T
authors.lastname: Bauer
authors.forename: R
authors.initials: R
authors.lastname: Zahn
mesh_terms: D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D001026:Coronary Artery Bypass; D004562:Electrocardiography; D006801:Humans; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D012815:Signal Processing, Computer-Assisted; D016019:Survival Analysis
chemical_list: D010975:Platelet Aggregation Inhibitors